View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar I. Belgyógyászati Klinika Budapest Korányi Sándor u. 2/A 1083

A csontritkulás a lakosság 9%-át érinti Magyarországon. Mindez közel 100 000 osteoporoticus csonttörést eredményez évente, amelyek közül a csípőtáji törések egy éven belüli közvetett mortalitása meghaladja a 35%-ot. Az osteoporosis közvetlen költségei éves szinten elérik a 25 milliárd forintot. Érthető, hogy a törési kockázat bárminemű költséghatékony csökkentése, az életminőség javításán túl, jelentős anyagi előnyökkel is jár. Erre a célra számos gyógyszer áll rendelkezésünkre napjainkban. Az osteoporosis gyógyszeres kezelésének középpontjában jelenleg a biszfoszfonátok állnak, amelyek erős antireszorptív tulajdonságúak, így a gyors csontvesztést és a törékenységet hatékonyan mérséklik. A közelmúltban regisztrált denosumab a RANK-ligandot semlegesítő hatásával éri el ugyanezt, azonban a kétféle hatóanyag között számos különbség fedezhető fel. A stroncium egyedülállóan új szintre állítja be a csontanyagcserét, azáltal a nem gyors csontvesztő, de fokozott törési kockázatú betegeknél is hatékony kezelési mód lehet. A kifejezetten súlyos vagy más kezelésre nem reagáló osteoporoticus betegek kezelésére pedig jól bevált a tisztán anabolikus teriparatid. Bizonyos esetekben a női hormonpótlásnak, a raloxifennek, a tibolonnak és a kalcitoninnak is van helye a csontritkulás terápiájában. Orv. Hetil., 2011, 152, 1320–1326.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Nikander, R., Sievänen, H., Heinonen, A. és mtsai: Targeted exercise against osteoporosis: A systematic review and meta-analysis for optimising bone strength throughout life. BMC Med., 2010, 8, 47.

    Heinonen A. , 'Targeted exercise against osteoporosis: A systematic review and meta-analysis for optimising bone strength throughout life ' (2010 ) 8 BMC Med. : 47 -.

    • Search Google Scholar
  • Prior, J. C., Barr, S. I., Chow, R. és mtsa: Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis. Canad. Med. Assoc. J., 1996, 155, 940–944.

    Chow R. , 'Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis ' (1996 ) 155 Canad. Med. Assoc. J. : 940 -944.

    • Search Google Scholar
  • Stevens, J. A., Olson, S.: Reducing falls and resulting hip fractures among older women. MMWR Recomm. Rep., 2000, 49 (RR-2), 3–12.

    Olson S. , 'Reducing falls and resulting hip fractures among older women ' (2000 ) 49 MMWR Recomm. Rep. : 3 -12.

    • Search Google Scholar
  • Audran, M., Briot, K.: Critical reappraisal of vitamin D deficiency. Joint Bone Spine, 2010, 77, 115–119.

    Briot K. , 'Critical reappraisal of vitamin D deficiency ' (2010 ) 77 Joint Bone Spine : 115 -119.

    • Search Google Scholar
  • Bonjour, J. P., Guéguen, L., Palacios, C. és mtsai: Minerals and vitamins in bone health: the potential value of dietary enhancement. Br. J. Nutr., 2009, 101, 1581–1596.

    Palacios C. , 'Minerals and vitamins in bone health: the potential value of dietary enhancement ' (2009 ) 101 Br. J. Nutr. : 1581 -1596.

    • Search Google Scholar
  • Bolland, M. J., Avenell, A., Baron, J. A. és mtsai: Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. Br. Med. J., 2010, 341, c3691.

    Baron J. A. , 'Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis ' (2010 ) 341 Br. Med. J. : c3691 -.

    • Search Google Scholar
  • Wang, T. K., Bolland, M. J., van Pelt, N. C. és mtsai: Relationships between vascular calcification, calcium metabolism, bone density, and fractures. J. Bone Miner. Res., 2010, 25, 2501–2509.

    Pelt N. C. , 'Relationships between vascular calcification, calcium metabolism, bone density, and fractures ' (2010 ) 25 J. Bone Miner. Res. : 2501 -2509.

    • Search Google Scholar
  • Lewis, J. R., Calver, J., Zhu, K. és mtsai: Calcium supplementation and the risk of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up. J. Bone Miner. Res., 2011, 26, 35–41.

    Zhu K. , 'Calcium supplementation and the risk of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up ' (2011 ) 26 J. Bone Miner. Res. : 35 -41.

    • Search Google Scholar
  • Manson, J. E., Allison, M. A., Carr, J. J. és mtsai: Women’s Health Initiative and Women’s Health Initiative-Coronary Artery Calcium Study Investigators: Calcium/vitamin D supplementation and coronary artery calcification in the Women’s Health Initiative. Menopause, 2010, 17, 683–691.

    Carr J. J. , 'Women’s Health Initiative and Women’s Health Initiative-Coronary Artery Calcium Study Investigators: Calcium/vitamin D supplementation and coronary artery calcification in the Women’s Health Initiative ' (2010 ) 17 Menopause : 683 -691.

    • Search Google Scholar
  • Wang, L., Manson, J. E., Song, Y. és mtsa: Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann. Intern. Med., 2010, 152, 315–323.

    Song Y. , 'Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events ' (2010 ) 152 Ann. Intern. Med. : 315 -323.

    • Search Google Scholar
  • Sato, Y., Honda, Y., Iwamoto, J. és mtsai: Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. J. Am. Med. Assoc., 2005, 293, 1082–1088.

    Iwamoto J. , 'Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial ' (2005 ) 293 J. Am. Med. Assoc. : 1082 -1088.

    • Search Google Scholar
  • North American Menopause Society: Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 2010, 17, 25–54.

    'Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society ' (2010 ) 17 Menopause : 25 -54.

    • Search Google Scholar
  • LaFleur, J., McAdam-Marx, C., Kirkness, C. és mtsa: Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature. Ann. Pharmacother., 2008, 42, 375–386.

    Kirkness C. , 'Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature ' (2008 ) 42 Ann. Pharmacother. : 375 -386.

    • Search Google Scholar
  • Mazziotti, G., Canalis, E., Giustina, A.: Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med., 2010, 123, 877–884.

    Giustina A. , 'Drug-induced osteoporosis: mechanisms and clinical implications ' (2010 ) 123 Am. J. Med. : 877 -884.

    • Search Google Scholar
  • Silverman, S. L., Lane, N. E.: Glucocorticoid-induced osteoporosis. Curr. Osteoporos. Rep., 2009, 7, 23–26.

    Lane N. E. , 'Glucocorticoid-induced osteoporosis ' (2009 ) 7 Curr. Osteoporos. Rep. : 23 -26.

    • Search Google Scholar
  • Straub, D. A.: Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr. Clin. Pract., 2007, 22, 286–296.

    Straub D. A. , 'Calcium supplementation in clinical practice: a review of forms, doses, and indications ' (2007 ) 22 Nutr. Clin. Pract. : 286 -296.

    • Search Google Scholar
  • North American Menopause Society: Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 2010, 17, 242–255.

    'Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society ' (2010 ) 17 Menopause : 242 -255.

    • Search Google Scholar
  • Lazovic, G., Radivojevic, U., Marinkovic, J.: Tibolone: the way to beat many a postmenopausal ailments. Expert Opin. Pharmacother., 2008, 9, 1039–1047.

    Marinkovic J. , 'Tibolone: the way to beat many a postmenopausal ailments ' (2008 ) 9 Expert Opin. Pharmacother. : 1039 -1047.

    • Search Google Scholar
  • Messalli, E. M., Scaffa, C.: Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int. J. Womens Health, 2010, 1, 11–20.

    Scaffa C. , 'Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update ' (2010 ) 1 Int. J. Womens Health : 11 -20.

    • Search Google Scholar
  • Kendler, D. L., Palacios, S., Cox, D. A. és mtsai: Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis. Osteoporos. Int., 2011 March 4. (Epub ahead of print.)

  • Palacios, S.: Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Curr. Med. Res. Opin., 2010, 26, 1553–1563.

    Palacios S. , 'Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis ' (2010 ) 26 Curr. Med. Res. Opin. : 1553 -1563.

    • Search Google Scholar
  • Swan, V. J., Hamilton, C. J., Jamal, S. A.: Lasofoxifene in osteoporosis and its place in therapy. Adv. Ther., 2010, 27, 917–932.

    Jamal S. A. , 'Lasofoxifene in osteoporosis and its place in therapy ' (2010 ) 27 Adv. Ther. : 917 -932.

    • Search Google Scholar
  • Dunford, J. E., Kwaasi, A. A., Rogers, M. J. és mtsai: Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J. Med. Chem., 2008, 51, 2187–2195.

    Rogers M. J. , 'Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase ' (2008 ) 51 J. Med. Chem. : 2187 -2195.

    • Search Google Scholar
  • Eastell, R., Walsh, J. S., Watts, N. B. és mtsa: Bisphosphonates for postmenopausal osteoporosis. Bone, 2011 Feb 22. (Epub ahead of print.)

  • Reid, D. M., Devogelaer, J. P., Saag, K. és mtsai: HORIZON investigators: Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial., 2009, 373, 1253–1263.

  • Stoch, S. A., Saag, K. G., Greenwald, M. és mtsai: Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J. Rheumatol., 2009, 36, 1705–1714.

    Greenwald M. , 'Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial ' (2009 ) 36 J. Rheumatol. : 1705 -1714.

    • Search Google Scholar
  • Orwoll, E., Ettinger, M., Weiss, S. és mtsai: Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med., 2000, 343, 604–610.

    Weiss S. , 'Alendronate for the treatment of osteoporosis in men ' (2000 ) 343 N. Engl. J. Med. : 604 -610.

    • Search Google Scholar
  • Orwoll, E. S., Miller, P. D., Adachi, J. D. és mtsai: Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res., 2010, 25, 2239–2250.

    Adachi J. D. , 'Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study ' (2010 ) 25 J. Bone Miner. Res. : 2239 -2250.

    • Search Google Scholar
  • Zhong, Z. M., Chen, J. T.: Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. Clin. Drug. Investig., 2009, 29, 349–357.

    Chen J. T. , 'Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials ' (2009 ) 29 Clin. Drug. Investig. : 349 -357.

    • Search Google Scholar
  • Black, D., Reid, I. R., Cauley, J. A. és mtsai: The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). American Society for Bone and Mineral Research Annual Meeting Abstracts, Toronto, Canada, 2010. október 15–20. [1070].

    Cauley J. A. , '', in The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). American Society for Bone and Mineral Research Annual Meeting Abstracts, 2010. október 15–20 , (2010 ) -.

  • Pazianas, M., Cooper, C., Ebetino, F. H. és mtsa: Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther. Clin. Risk Manag., 2010, 6, 325–343.

    Ebetino F. H. , 'Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis ' (2010 ) 6 Ther. Clin. Risk Manag. : 325 -343.

    • Search Google Scholar
  • Watts, N. B., Diab, D. L.: Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab., 2010, 95, 1555–1565.

    Diab D. L. , 'Long-term use of bisphosphonates in osteoporosis ' (2010 ) 95 J. Clin. Endocrinol. Metab. : 1555 -1565.

    • Search Google Scholar
  • Cummings, S. R., San Martin, J., McClung, M. R. és mtsai: FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med., 2009, 361, 756–765.

    McClung M. R. , 'FREEDOM Trial: Denosumab for prevention of fractures in postmenopausal women with osteoporosis ' (2009 ) 361 N. Engl. J. Med. : 756 -765.

    • Search Google Scholar
  • Brown, J. P., Prince, R. L., Deal, C. és mtsai: Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J. Bone Miner. Res., 2009, 14, 1–34.

    Deal C. , 'Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial ' (2009 ) 14 J. Bone Miner. Res. : 1 -34.

    • Search Google Scholar
  • Reid, I. R., Miller, P. D., Brown, J. P. és mtsai, Denosumab Phase 3 Bone Histology Study Group: Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J. Bone Miner. Res., 2010, 25, 2256–2265.

    Brown J. P. , 'Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies ' (2010 ) 25 J. Bone Miner. Res. : 2256 -2265.

    • Search Google Scholar
  • Jamal, S. A., Ljunggren, O., Stehman-Breen, C. és mtsai: The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function. European Calcified Tissue Society Congress Abstracts, Glasgow, Scotland, 2010. június 26–30, PP355.

  • Cranney, A., Papaioannou, A., Zytaruk, N. és mtsai: Clinical Guidelines Committee of Osteoporosis Canada: Parathyroid hormone for the treatment of osteoporosis: a systematic review. Canad. Med. Assoc. J., 2006, 175, 52–59.

    Zytaruk N. , 'Clinical Guidelines Committee of Osteoporosis Canada: Parathyroid hormone for the treatment of osteoporosis: a systematic review ' (2006 ) 175 Canad. Med. Assoc. J. : 52 -59.

    • Search Google Scholar
  • Orwoll, E. S., Scheele, W. H., Paul, S. és mtsai: The effect of teriparatide (human parathyroid hormone [1-34]) therapy on bone density in men with osteoporosis. J. Bone Miner. Res., 2003, 18, 9–17.

    Paul S. , 'The effect of teriparatide (human parathyroid hormone [1-34]) therapy on bone density in men with osteoporosis ' (2003 ) 18 J. Bone Miner. Res. : 9 -17.

    • Search Google Scholar
  • Lane, N. E., Sanchez, S., Modin, G. W. és mtsai: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest., 1998, 102, 1627–1633.

    Modin G. W. , 'Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial ' (1998 ) 102 J. Clin. Invest. : 1627 -1633.

    • Search Google Scholar
  • Pietrogrande, L.: Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis. Int. J. Womens Health, 2010, 1, 193–203.

    Pietrogrande L. , 'Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis ' (2010 ) 1 Int. J. Womens Health : 193 -203.

    • Search Google Scholar
  • Reginster, J. Y., Felsenberg, D., Boonen, S. és mtsai: Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum., 2008, 58, 1687–1695.

    Boonen S. , 'Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial ' (2008 ) 58 Arthritis Rheum. : 1687 -1695.

    • Search Google Scholar
  • Seeman, E., Boonen, S., Borgström, F. és mtsai: Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone, 2010, 46, 1038–1042.

    Borgström F. , 'Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age ' (2010 ) 46 Bone : 1038 -1042.

    • Search Google Scholar
  • Reginster, J. Y., Kaufman, J. M., Goemaere, S. és mtsai: Long-term treatment of postmenopausal osteoporotic women with strontium ranelate: Results at 10 years. Osteopor. Int., 2010, 21 (S5), S665.

    Goemaere S. , 'Long-term treatment of postmenopausal osteoporotic women with strontium ranelate: Results at 10 years ' (2010 ) 21 Osteopor. Int. : S665 -.

    • Search Google Scholar
  • Lyritis, G. P., Paspati, I., Karachalios, T. és mtsai: Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop. Scand. Suppl., 1997, 275, 112–114.

    Karachalios T. , 'Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study ' (1997 ) 275 Acta Orthop. Scand. Suppl. : 112 -114.

    • Search Google Scholar
  • Bolland, M. J., Ames, R. W., Horne, A. M. és mtsai: The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporos. Int., 2007, 18, 479–486.

    Horne A. M. , 'The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women ' (2007 ) 18 Osteoporos. Int. : 479 -486.

    • Search Google Scholar
  • Yue, J., Zhang, X., Dong, B. és mtsa: Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause, 2010, 17, 1071–1079.

    Dong B. , 'Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials ' (2010 ) 17 Menopause : 1071 -1079.

    • Search Google Scholar
  • Delmas, P. D.: How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone, 2000, 27, 1–3.

    Delmas P. D. , 'How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? ' (2000 ) 27 Bone : 1 -3.

    • Search Google Scholar
  • Horváth C., Lakatos P., Marton I. és mtsai: Ajánlás az osteoporosis és más metabolikus csontbetegségek diagnosztikájára 2004-ben. Ca és Csont, 2003, 6, 78–87.

    Marton I. , 'Ajánlás az osteoporosis és más metabolikus csontbetegségek diagnosztikájára 2004-ben ' (2003 ) 6 Ca és Csont : 78 -87.

    • Search Google Scholar
  • Black, D. M., Delmas, P. D., Eastell, R. és mtsai, for the HORIZON Pivotal Fracture Trial: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med., 2007, 356, 1809–1822.

    Eastell R. , 'Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis ' (2007 ) 356 N. Engl. J. Med. : 1809 -1822.

    • Search Google Scholar
  • Chesnut, C. H. III., Skag, A., Christiansen, C. és mtsai, for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE): Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res., 2004, 19, 1241–1249.

    Christiansen C. , 'Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis ' (2004 ) 19 J. Bone Miner. Res. : 1241 -1249.

    • Search Google Scholar
  • Sambrook, P., Cranney, A., Adachi, J. D.: Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. Curr. Med. Res. Opin., 2001, 26, 599–604.

    Adachi J. D. , 'Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA ' (2001 ) 26 Curr. Med. Res. Opin. : 599 -604.

    • Search Google Scholar
  • Harris, S. T., Watts, N. B., Genant, H. K. és mtsai: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. J. Am. Med. Assoc., 1999, 282, 1344–1352.

    Genant H. K. , 'Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group ' (1999 ) 282 J. Am. Med. Assoc. : 1344 -1352.

    • Search Google Scholar
  • Black, D. M., Cummings, S. R., Karpf, D. B. és mtsai: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet, 1996, 348, 1535–1541.

    Karpf D. B. , 'Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group ' (1996 ) 348 Lancet : 1535 -1541.

    • Search Google Scholar
  • Cummings, S. R., Black, D. M., Thompson, D. E. és mtsai: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J. Am. Med. Assoc., 1998, 280, 2077–2082.

    Thompson D. E. , 'Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial ' (1998 ) 280 J. Am. Med. Assoc. : 2077 -2082.

    • Search Google Scholar
  • Hansdóttir, H.: Raloxifene for older women: a review of the literature. Clin. Interv. Aging, 2008, 3, 45–50.

    Hansdóttir H. , 'Raloxifene for older women: a review of the literature ' (2008 ) 3 Clin. Interv. Aging : 45 -50.

    • Search Google Scholar
  • Lakatos P., Takács I., Szekeres L., Poór Gy. és a Reumatológiai és Fizioterápiás Szakmai Kollégium: A korral járó és a kortikoszteroidok indukálta osteoporosis diagnosztikus és terápiás protokollja – 2011. In: Háziorvosi Útmutató – Klinikai Irányelvek Kézikönyve. Medition Kiadó, Budapest, 2010, 2010/3: 215–224.

    Poór Gy. , '', in Háziorvosi Útmutató – Klinikai Irányelvek Kézikönyve, 2010/3 , (2010 ) -.